Olema Pharmaceuticals inc
OLMAHealthcare|Biotechnology|USA
$11.91
-0.38 (-3.09%)
Tangible Book
$5.50
Earnings Power
$4.80
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07085767 Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Breast Cancer, Locally Advanced Breast Cancer | P3 | Recruiting | 1,000 | RCT, Double-blind | Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo |
| NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Breast Cancer, Advanced Breast Cancer | P3 | Recruiting | 510 | RCT, Open-label | Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane |
| NCT06784193 Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | P1 | Recruiting | 180 | RCT, Open-label | OP-3136, Fulvestrant, Palazestrant |
| NCT05508906 Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | Metastatic Breast Cancer, ER-positive Breast Cancer | P1 | Recruiting | 190 | Open-label | Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib |
| NCT05266105 A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients | Breast Cancer | P1 | Active | 60 | Open-label | Palazestrant, Palbociclib |
| NCT04505826 A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer | P1P2 | Completed | 153 | Open-label | OP-1250 |